Stock Price & Analysis

The S1 support level for LUCD Stock is $1.21 ,The R1 resistant level for LUCD Stock is $1.52.

As of the end of day on 2025-03-10, the price of LUCD Stock was $1.25.

The target price for LUCD Stock according to analyst rating is 7.00, with the highest price target at 7.00 and the lowest at 7.00. Analysts have a Moderate Buy rating on LUCD Stock overall.

The market cap of LUCD is $116.3M.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics technology company. The Company is focused on patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, that leads to esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The Company’s products include EsoGuard, and EsoCheck. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells in office procedures. It consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter from which a soft silicone balloon with textured ridges emerges to swab surface esophageal cells. It is also developing EsoCure, is an Esophageal Ablation Device that allows a clinician to treat dysplastic BE before it can progress to EAC.

LUCD has a total of 70 employees.